abstract |
The invention relates to the treatment of cardiac dysfunction. In particular, it is assumed that certain compounds, double agonists of glucagon-GLP-1, have a positive inotropic effect, while maintaining the energy balance in the heart, and they may be superior to known inotropic agents, such as dobutamine, norepinephrine and glucagon. |